Rosalind Advisors Inc. Sells 73,798 Shares of COMPASS Pathways plc (NASDAQ:CMPS)

Rosalind Advisors Inc. reduced its stake in shares of COMPASS Pathways plc (NASDAQ:CMPS) by 9.4% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 707,625 shares of the company’s stock after selling 73,798 shares during the period. COMPASS Pathways accounts for approximately 1.3% of Rosalind Advisors Inc.’s investment portfolio, making the stock its 20th biggest position. Rosalind Advisors Inc. owned approximately 1.03% of COMPASS Pathways worth $2,675,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. acquired a new position in COMPASS Pathways in the fourth quarter valued at $41,000. Flagship Harbor Advisors LLC acquired a new position in shares of COMPASS Pathways in the 4th quarter valued at about $43,000. Wealthfront Advisers LLC bought a new stake in shares of COMPASS Pathways during the 4th quarter valued at about $43,000. Conservest Capital Advisors Inc. grew its stake in COMPASS Pathways by 28.9% during the fourth quarter. Conservest Capital Advisors Inc. now owns 13,363 shares of the company’s stock worth $51,000 after purchasing an additional 3,000 shares during the period. Finally, Essential Planning LLC. bought a new stake in COMPASS Pathways in the fourth quarter worth approximately $70,000. 46.19% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on CMPS shares. HC Wainwright reiterated a “buy” rating and issued a $45.00 price objective on shares of COMPASS Pathways in a research note on Tuesday, March 4th. Royal Bank of Canada reiterated an “outperform” rating and set a $18.00 price objective on shares of COMPASS Pathways in a report on Wednesday, January 15th. Cantor Fitzgerald restated an “overweight” rating on shares of COMPASS Pathways in a research note on Friday, March 28th. Stifel Nicolaus began coverage on COMPASS Pathways in a research note on Thursday, February 27th. They set a “buy” rating and a $11.00 price target on the stock. Finally, Canaccord Genuity Group decreased their price objective on COMPASS Pathways from $23.00 to $15.00 and set a “buy” rating for the company in a report on Friday, February 28th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $20.20.

COMPASS Pathways Stock Performance

Shares of CMPS opened at $3.88 on Tuesday. The firm has a market capitalization of $359.57 million, a P/E ratio of -1.76 and a beta of 2.34. COMPASS Pathways plc has a 52 week low of $2.49 and a 52 week high of $9.63. The stock has a 50 day moving average price of $3.34 and a two-hundred day moving average price of $4.16. The company has a debt-to-equity ratio of 0.15, a quick ratio of 8.91 and a current ratio of 8.91.

COMPASS Pathways (NASDAQ:CMPS) last announced its earnings results on Thursday, February 27th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.01). Equities analysts forecast that COMPASS Pathways plc will post -2.33 earnings per share for the current fiscal year.

COMPASS Pathways Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.